TICKERNERD
Menu
CAPRCAPRHealthcare · Biotechnology

CAPR Stock Forecast: Capricor Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$8.81
+5.26% on the day

The 9 Wall Street analysts covering Capricor Therapeutics, Inc. hold a median 12-month price target of $27 — +200.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 14 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$486.6M
Ticker Nerd rank
9 / 100
Median analyst target
$27
Analysts covering
9
Revenue$0.0
Operating income−$42.9M
Net income−$40.7M
Free cash flow−$37.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.3%
1M
+32.5%
YTD
−69.5%
1Y
+38.5%
From 52W high
−75.1%
From 52W low
+128.8%
$4
$35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CAPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Capricor Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
53
Quality
46
Value
36
Momentum
33
Growth
27
Accruals
27
Revisions
26
Volatility
13
Issuance
7

Size (53): Smaller than most of the companies we track.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CAPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CAPR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26CAPRHigh $54Median $27Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
3 Buy6 Hold0 Sell
Low $7Median $27High $54

The green dot is the last close — the median target sits +200.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
1 Sept 2026Piper SandlerUpgradeOverweight$2.00 → $25
14 Aug 2026Cantor FitzgeraldUpgradeOverweight—
14 Aug 2026Cantor FitzgeraldUpgradeOverweight$3.50 → $28
31 July 2026Jones TradingDowngradeHold—
31 July 2026Jones TradingDowngradeHold—
30 July 2026Cantor FitzgeraldDowngradeNeutral$62 → $3.50
30 July 2026Cantor FitzgeraldDowngradeNeutral—
30 July 2026HC Wainwright & Co.DowngradeNeutral—
30 July 2026HC Wainwright & Co.DowngradeNeutral—
30 July 2026Piper SandlerDowngradeNeutral—
30 July 2026Piper SandlerDowngradeNeutral$58 → $2.00
13 May 2026HC Wainwright & Co.ReiteratesBuy$60
13 May 2026HC Wainwright & Co.ReiteratesBuy—
13 Mar 2026B. Riley SecuritiesMaintainsBuy—
13 Mar 2026HC Wainwright & Co.ReiteratesBuy—
13 Mar 2026Piper SandlerReiteratesOverweight—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
15 Dec 2025B. Riley SecuritiesReiteratesBuy—
10 Dec 2025Piper SandlerReiteratesOverweight—
8 Dec 2025OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CAPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CAPR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Capricor Therapeutics, Inc. returned +38.5% against +17.0% for the S&P 500, dividends included.

CAPR vs S&P 500, last 12 monthsTotal return, rebased to 100
0100200300400500600Oct 25Jan 26Apr 26Jul 26CAPRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CAPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

Capricor Therapeutics, Inc. (CAPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 89% of US stocks

Price / sales
—
Price / book
2.1×

Cheaper than 44% of US stocks

EV / EBITDA
−2.6×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−73.7%

Higher than 17% of US stocks

Return on assets
−33.6%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Capricor Therapeutics, Inc. (CAPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Capricor Therapeutics, Inc. has a market value of $486.6M and an enterprise value of $339.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$129.4M.

  • Diluted earnings per share, trailing twelve months: $−2.45.

  • Free cash flow in the twelve months to 30 June 2026: −$129.8M.

  • Shares outstanding: 58.1M.

  • Trailing P/E: −4.0×; forward P/E: −6.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Capricor Therapeutics, Inc. employs 231 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

CAPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CAPRCapricor Therapeutics, Inc.$486.6M
9
EIKNEikon Therapeutics, Inc.$506.4M
1
OVIDOvid Therapeutics, Inc.$511.4M
68
ZURAZura Bio Ltd.$494.3M
33
ARTVArtiva Biotherapeutics, Inc.$492.7M
40
ENTXEntera Bio Ltd.$488.3M
49
IRDOpus Genetics, Inc.$485.9M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Capricor Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CAPR news & analysis

Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Deadline on September 28, 2026

Newsfile Corp · 14 Sept 2026negative

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026. The firm is advising affected investors to contact it before the September 28, 2026 deadline.

Why it matters — A CAPR watcher would care because the company now faces a securities class action lawsuit tied to a defined class period, representing a notable legal and financial risk for the company.

Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

GlobeNewsWire · 14 Sept 2026negative

Glancy Prongay Wolke & Rotter LLP reminded investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in a securities fraud class action brought against Capricor Therapeutics. The lawsuit covers investors who acquired CAPR securities between December 17, 2025 and July 26, 2026.

Why it matters — A securities fraud class action with a lead plaintiff deadline has been filed against Capricor, which CAPR shareholders should be aware of as it relates to the period from December 2025 through July 2026.

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

GlobeNewsWire · 14 Sept 2026negative

Law firm Schall, Brown & Schwartz LLP is reminding investors of a class action securities fraud lawsuit against Capricor Therapeutics brought under the Securities Exchange Act of 1934. The firm says investors have an opportunity to lead the case.

Why it matters — A securities fraud class action could carry legal and financial implications for Capricor and is directly relevant to shareholders and potential investors in the company.

Capricor Deadline: CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

PRNewsWire · 13 Sept 2026negative

Rosen Law Firm reminded purchasers of Capricor Therapeutics securities between December 17, 2025 and July 26, 2026 of the September 28, 2026 lead plaintiff deadline in a securities fraud lawsuit against the company.

Why it matters — CAPR shareholders who bought stock during the class period may be affected by the pending securities fraud litigation and the approaching lead plaintiff deadline.

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

MarketBeat · 13 Sept 2026neutral

MarketBeat published an article highlighting three small-cap biotech companies, including Capricor Therapeutics, noting that for these companies a single date on the calendar — such as a clinical trial readout or an FDA decision — can matter more than a quarter's worth of earnings. The article notes these companies often burn cash for years without product revenue while betting on those catalysts.

Why it matters — CAPR watchers would care because the article flags Capricor as one of several small-cap biotechs with a binary, calendar-driven catalyst (a trial readout or FDA decision) that could carry outsized significance for the company's outlook.

FAQ

Frequently asked questions about CAPR stock

What is the CAPR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Capricor Therapeutics, Inc. have a median 12-month price target of $27, with estimates ranging from $7 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CAPR stock a buy right now?

Of the 9 analysts covering Capricor Therapeutics, Inc., 3 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Capricor Therapeutics, Inc. 9 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CAPR?

As at 14 Sept 2026, Capricor Therapeutics, Inc. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (53 of 100).

Will CAPR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +200.8% from the last close, and Ticker Nerd's factor model ranks Capricor Therapeutics, Inc. 9 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CAPR stock forecast for 2030?

No analyst covering Capricor Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CAPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $54 over the next 12 months.

How has CAPR stock performed over the past year?

Capricor Therapeutics, Inc. returned +38.5% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Capricor Therapeutics, Inc. do?

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases.

What is the latest news on CAPR?

The most recent item we track (Newsfile Corp, 14 Sept 2026): "Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Deadline on September 28, 2026". Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Capricor Therapeutics on behalf of investors who purchased or acquired Capricor securities between December 17, 2025 and July 26, 2026. The firm is advising affected investors to contact it before the September 28, 2026 deadline.

Company

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for rare diseases. Its lead program, Deramiocel, is an allogeneic cardiac-derived cell therapy being advanced for Duchenne muscular dystrophy, a severe muscle-wasting disorder with significant unmet medical need. The company also develops engineered exosomes through its StealthX platform, which is designed to deliver nucleic acids, proteins, and small molecules for applications in vaccinology and other therapeutic areas. Capricor Therapeutics operates in the healthcare and life sciences sector, where its work spans regenerative medicine, rare-disease treatment, and next-generation biologics. The company’s current portfolio centers on advanced clinical and preclinical programs that aim to address complex conditions through targeted biological mechanisms rather than traditional small-molecule approaches.

CEO Dr. Linda Marbán Ph.D. · 231 employees · United States · https://www.capricor.com